Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting
November 05, 2015 09:22 ET
|
Curis, Inc.
LEXINGTON, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment...
Curis Announces Presentation of Preclinical Data From Small Molecule PD-L1/VISTA and IRAK4 Programs at the AACR-NCI-EORTC International Conference
November 02, 2015 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment...
Curis to Release Third Quarter 2015 Financial Results and Hold Conference Call on November 9, 2015
November 02, 2015 06:30 ET
|
Curis, Inc.
LEXINGTON, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment...
Curis Expands Cancer Drug Pipeline With Small Molecule PD-L1/ VISTA Immune Checkpoint Antagonist and IRAK4 Kinase Inhibitors
October 19, 2015 07:00 ET
|
Curis, Inc.
Company exercises options under Aurigene collaboration to license orally available small molecules for immuno-oncology and precision oncology
Curis selects program of small molecules targeting...
Curis to Present at the BIO Investor Forum
October 14, 2015 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., Oct. 14, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment...
Curis to Participate in Upcoming Investor Conferences
September 02, 2015 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., Sept. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment...
Curis Reports Second Quarter 2015 Financial Results
August 06, 2015 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment...
Curis to Release Second Quarter 2015 Financial Results and Hold Conference Call on August 6, 2015
July 30, 2015 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., July 30, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment...
Curis to Present CUDC-907 Clinical Data at the 20th Congress of the European Hematology Association and the 13th International Congress on Malignant Lymphoma
June 10, 2015 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., June 10, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment...
Curis Reports CUDC-907 Data From the Ongoing Phase 1 Trial at the 2015 ASCO Annual Meeting
May 31, 2015 09:00 ET
|
Curis, Inc.
--CUDC-907 (HDAC and PI3K Inhibitor) Demonstrates Objective Responses, Including
Complete Responses, in Patients With Relapsed/ Refractory DLBCL--
--Expansion Phase Ongoing in Patients With...